tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Shanghai Pharmaceuticals Acquires 10% Stake in Finance Company

Story Highlights
  • Shanghai Pharmaceuticals focuses on pharmaceutical products and healthcare services.
  • The company acquired a 10% equity interest in Finance Company to boost its market position.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Shanghai Pharmaceuticals Acquires 10% Stake in Finance Company

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Shanghai Pharmaceuticals Holding Co ( (HK:2607) ) just unveiled an announcement.

Shanghai Pharmaceuticals Holding Co., Ltd. has announced the execution of a Share Transfer Agreement to acquire a 10% equity interest in Finance Company from SIIC Dongtan. This strategic acquisition is expected to enhance the company’s financial capabilities and strengthen its market position in the pharmaceutical industry.

The most recent analyst rating on (HK:2607) stock is a Buy with a HK$14.50 price target. To see the full list of analyst forecasts on Shanghai Pharmaceuticals Holding Co stock, see the HK:2607 Stock Forecast page.

More about Shanghai Pharmaceuticals Holding Co

Shanghai Pharmaceuticals Holding Co., Ltd. is a major player in the pharmaceutical industry in China, focusing on the production and distribution of pharmaceutical products and healthcare services.

YTD Price Performance: -1.81%

Average Trading Volume: 4,601,117

Technical Sentiment Signal: Strong Buy

Current Market Cap: HK$66.94B

For detailed information about 2607 stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1